Search research articles
Contact Us
Filters
Showing results (91-100 of 227) with videos related to
Page
of 23
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 25, 2009
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma
Daniel C Cho, Igor Puzanov, Meredith M Regan, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 26, 2007
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
David E Avigan, Baldev Vasir, Daniel J George, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Urologic Oncology
|
May 11, 2010
Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma
Aymen A Elfiky, Daniel C Cho, David F McDermott, et al.
The Lancet. Oncology
|
April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Toni K Choueiri, David F McDermott, Jaime Merchan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
Ravi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Nature Medicine
|
April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Wenxin Xu, Maneka Puligandla, Judith Manola, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 12, 2024
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy
David J Einstein, Brian Halbert, Thomas Denize, et al.
Cancer
|
May 21, 2016
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
Rana R McKay, Guillermo De Velasco, Lillian Werner, et al.
Page
of 23
Search research articles
Search
Showing results (91-100 of 227) with videos related to
Sort By:
Page
of 23
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 25, 2009
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma
Daniel C Cho, Igor Puzanov, Meredith M Regan, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 26, 2007
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
David E Avigan, Baldev Vasir, Daniel J George, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Urologic Oncology
|
May 11, 2010
Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma
Aymen A Elfiky, Daniel C Cho, David F McDermott, et al.
The Lancet. Oncology
|
April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Toni K Choueiri, David F McDermott, Jaime Merchan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
Ravi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Nature Medicine
|
April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Wenxin Xu, Maneka Puligandla, Judith Manola, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 12, 2024
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy
David J Einstein, Brian Halbert, Thomas Denize, et al.
Cancer
|
May 21, 2016
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
Rana R McKay, Guillermo De Velasco, Lillian Werner, et al.
Page
of 23